X4 Pharmaceuticals Net Worth
X4 Pharmaceuticals Net Worth Breakdown | XFOR |
X4 Pharmaceuticals Net Worth Analysis
X4 Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including X4 Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of X4 Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform X4 Pharmaceuticals' net worth analysis. One common approach is to calculate X4 Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares X4 Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing X4 Pharmaceuticals' net worth. This approach calculates the present value of X4 Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of X4 Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate X4 Pharmaceuticals' net worth. This involves comparing X4 Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into X4 Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if X4 Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding X4 Pharmaceuticals' net worth research are outlined below:
| X4 Pharmaceuticals generated a negative expected return over the last 90 days | |
| X4 Pharmaceuticals has high historical volatility and very poor performance | |
| X4 Pharmaceuticals has some characteristics of a very speculative penny stock | |
| X4 Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (101.17 M) with profit before overhead, payroll, taxes, and interest of 628 K. | |
| X4 Pharmaceuticals currently holds about 47.38 M in cash with (96.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 59.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from globenewswire.com: X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025 |
X4 Pharmaceuticals Quarterly Good Will |
|
X4 Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in X4 Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to X4 Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know X4 Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as X4 Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading X4 Pharmaceuticals backward and forwards among themselves. X4 Pharmaceuticals' institutional investor refers to the entity that pools money to purchase X4 Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Pale Fire Capital Se | 2024-12-31 | 1.4 M | Schonfeld Strategic Advisors Llc | 2024-12-31 | 1.4 M | Northern Trust Corp | 2024-12-31 | 1.4 M | Gsa Capital Partners Llp | 2024-12-31 | 1.3 M | Ubs O'connor Llc | 2024-12-31 | 1.3 M | Ubs Group Ag | 2024-12-31 | 923.1 K | Group One Trading, Lp | 2024-12-31 | 797.4 K | Point72 Asset Management, L.p. | 2024-12-31 | 650 K | Jane Street Group Llc | 2024-12-31 | 583.5 K | Bain Capital Life Sciences Investors, Llc | 2024-12-31 | 16.9 M | Nea Management Company, Llc | 2024-12-31 | 15 M |
Follow X4 Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 51.1 M.Market Cap |
|
Project X4 Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.70) | (0.74) | |
| Return On Capital Employed | (0.99) | (1.04) | |
| Return On Assets | (0.62) | (0.65) | |
| Return On Equity | (2.28) | (2.16) |
When accessing X4 Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures X4 Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of X4 Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate X4 Pharmaceuticals' management efficiency
X4 Pharmaceuticals has return on total asset (ROA) of (0.4655) % which means that it has lost $0.4655 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2635) %, meaning that it created substantial loss on money invested by shareholders. X4 Pharmaceuticals' management efficiency ratios could be used to measure how well X4 Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/20/2025, Return On Tangible Assets is likely to drop to -0.74. In addition to that, Return On Capital Employed is likely to drop to -1.04. At this time, X4 Pharmaceuticals' Other Current Assets are relatively stable compared to the past year. As of 03/20/2025, Net Tangible Assets is likely to grow to about 68.5 M, while Non Current Assets Total are likely to drop slightly above 19.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.33 | 0.31 | |
| Tangible Book Value Per Share | 0.22 | 0.21 | |
| Enterprise Value Over EBITDA | (0.91) | (0.95) | |
| Price Book Value Ratio | 2.63 | 2.76 | |
| Enterprise Value Multiple | (0.91) | (0.95) | |
| Price Fair Value | 2.63 | 2.76 | |
| Enterprise Value | 124.4 M | 130.6 M |
The management team at X4 Pharmaceuticals has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific X4 Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on X4 Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases X4 Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
X4 Pharmaceuticals time-series forecasting models is one of many X4 Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary X4 Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
X4 Pharmaceuticals Earnings per Share Projection vs Actual
X4 Pharmaceuticals Corporate Management
| Robert Arbeit | Senior Research | Profile | |
| Mary DiBiase | Chief Officer | Profile | |
| Keith MD | Founder Board | Profile | |
| Pharm MPH | Vice Communications | Profile | |
| Renato Skerlj | Founder | Profile |
Already Invested in X4 Pharmaceuticals?
The danger of trading X4 Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of X4 Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than X4 Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile X4 Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.